Article
Oncology
Liany Luna-Dulcey, James Almada da Silva, Veronica Jimenez-Renard, Eduardo Caleiras, Silvana Mouron, Miguel Quintela-Fandino, Marcia R. Cominetti
Summary: This study focused on a semi-synthetic compound derived from [6]-gingerol, named SSi6, which demonstrated antitumor and antimetastatic effects in TNBC cells without causing significant toxic effects in vivo. Results showed that SSi6 effectively inhibited the growth of primary tumors and prevented metastatic progression from lymph nodes to lungs. Additionally, it blocked the progression of metastases from lymph nodes to other visceral organs in preclinical xenograft models, suggesting its potential as a complementary therapy for TNBC.
Article
Medicine, General & Internal
A. Bardia, S. A. Hurvitz, S. M. Tolaney, D. Loirat, K. Punie, M. Oliveira, A. Brufsky, S. D. Sardesai, K. Kalinsky, A. B. Zelnak, R. Weaver, T. Traina, F. Dalenc, P. Aftimos, F. Lynce, S. Diab, J. Cortes, J. O'Shaughnessy, V Dieras, C. Ferrario, P. Schmid, L. A. Carey, L. Gianni, M. J. Piccart, S. Loibl, D. M. Goldenberg, Q. Hong, M. S. Olivo, L. M. Itri, H. S. Rugo
Summary: Patients with metastatic triple-negative breast cancer treated with Sacituzumab govitecan had significantly longer progression-free and overall survival compared to standard chemotherapy, but experienced more frequent myelosuppression and diarrhea as adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Tong Liu, Cheng Liu, Meisi Yan, Lei Zhang, Jing Zhang, Min Xiao, Zhigao Li, Xiaofan Wei, Hongquan Zhang
Summary: This study characterizes the microenvironment of lymph node metastasized tumors (LNMT) and primary tumors (PT) in breast cancer. The results show that T cell activation, cytotoxicity, and proliferation are suppressed in LNMT compared to PT. CD4(+)CXCL13(+) T cells in LNMT are more likely to become exhausted. LAMP3(+) dendritic cells in LNMT have lower T cell priming and activating ability compared to PT. PLA2G2A(+) cancer-associated fibroblasts, enriched in HER2(+) breast cancer patients, promote immune infiltration. Additionally, the antigen-presentation pathway is downregulated in malignant cells of the metastatic lymph node.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Sandra D. Scherer, Alessandra Riggio, Fadi Haroun, Yoko S. DeRose, H. Atakan Ekiz, Maihi Fujita, Jennifer Toner, Ling Zhao, Zheqi Li, Steffi Oesterreich, Ahmed A. Samatar, Alana L. Welm
Summary: This study developed an immune-humanized PDX model for studying endocrine-resistant ER+ breast cancer, which contains a naturally occurring ESR1 mutation and recapitulates the lymphocyte-excluded and myeloid-rich tumor microenvironment of human ER+ breast tumors. The model provides a platform for studying mechanisms of endocrine resistance and tumor-immune interactions in a clinically relevant in vivo setting.
BREAST CANCER RESEARCH
(2021)
Article
Oncology
Gloria Echeverria, Shirong Cai, Yizheng Tu, Jiansu Shao, Emily Powell, Abena B. Redwood, Yan Jiang, Aaron McCoy, Amanda L. Rinkenbaugh, Rosanna Lau, Alexander J. Trevarton, Chunxiao Fu, Rebekah Gould, Elizabeth E. Ravenberg, Lei Huo, Rosalind Candelaria, Lumarie Santiago, Beatriz E. Adrada, Deanna L. Lane, Gaiane M. Rauch, Wei T. Yang, Jason B. White, Jeffrey T. Chang, Stacy L. Moulder, W. Fraser Symmans, Susan G. Hilsenbeck, Helen Piwnica-Worms
Summary: This study established 369 orthotopic PDX models of breast cancer and found that treatment-resistant cancers were more likely to be successfully engrafted. The molecular subtype of breast cancer was not associated with engraftment rate. A statistical model predictive of engraftment was developed based on clinical indicators. These breast cancer models are valuable for clinical treatment and biomarker research.
Article
Oncology
Ziqi Li, Erika Belitzky, Ondrej Blaha, Alessandra Cavaliere, Samantha R. R. Katz, Mariam Aboian, Lindy Melegari, Khashayar Rajabimoghadam, Stephen Kurpiewski, Xiaohua Zhu, Bernadette Marquez-Nostra
Summary: This study aimed to evaluate the effects of a specific drug (Dasatinib) on triple-negative breast cancer (TNBC) cells, specifically the impact on gpNMB expression, and to explore the efficacy of combination therapy. The findings demonstrated that Dasatinib increased gpNMB expression and enhanced the effectiveness of antibody drug conjugates. Therefore, these findings are significant for combination therapy in TNBC.
Article
Oncology
Jose P. Leone, Noah Graham, Julieta Leone, Sara M. Tolaney, Bernardo A. Leone, Rachel A. Freedman, Michael J. Hassett, Carlos T. Vallejo, Eric P. Winer, Nancy U. Lin, Nabihah Tayob
Summary: This study developed a tool called "ESTIMATE-TN" to assess the risk of breast cancer-specific mortality (BCSM), non-BCSM, and all-cause mortality in non-metastatic triple-negative breast cancer (TNBC) patients. The tool allows input of patient and tumor characteristics and provides a nonparametric estimate of cumulative risks using Gray's subdistribution method.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Yuxuan Han, Kazushi Azuma, Shinya Watanabe, Kentaro Semba, Jun Nakayama
Summary: Most studies on breast cancer metastasis have focused on triple-negative breast cancer cells, leading to a poor understanding of the metastatic ability of different subtypes of breast cancer. This research aimed to evaluate the metastatic abilities of HER2-positive breast cancer cell lines through injection experiments. The study identified certain cell lines with strong bone metastasis abilities but weak lung metastasis abilities.
CLINICAL & EXPERIMENTAL METASTASIS
(2022)
Review
Oncology
Xia Qiu, Tianjiao Zhao, Ran Luo, Ran Qiu, Zhaoming Li
Summary: TNBC is a subtype of breast cancer that lacks ER, PR, and HER-2 receptors. TAMs are macrophages infiltrating the tumor, derived from circulating blood mononuclear cells, and play a role in the occurrence and metastasis of TNBC, possibly serving as potential biomarkers for prognosis prediction.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Garrett F. Beeghly, Candace Thomas, Jessica X. Yuan, Alexandra R. Harris, Jennifer M. Munson
Summary: The rising survival rate of early-stage breast cancer in the United States has led to an increasing population of women in remission at risk for distant recurrence, with brain metastases showing a particularly poor prognosis. Tissue-engineered models based on patient tumor resections have revealed distinct cellular and matrix components in brain metastases compared to primary resections or non-cancerous controls. The observed deposition of collagen I after brain metastasis in their models suggests a potential enhancement of breast cancer invasion, providing a novel platform for studying tumor-stroma interactions and therapeutic screening for metastatic breast cancer management.
BIOENGINEERING-BASEL
(2022)
Article
Biochemical Research Methods
Xizhe Xie, Jingyun Wang, Liuwei Zhang, Shuang Zeng, Xiaohui Su, Qixian Chen
Summary: By releasing immunostimulatory drugs, potent innate and adaptive antitumor immunities were successfully activated for precise antitumor therapy, showing significant inhibition on the growth of tumor and distant pulmonary metastasis.
BIOCONJUGATE CHEMISTRY
(2021)
Article
Biochemistry & Molecular Biology
Xiaoqiang Wang, Karineh Petrossian, Miao-Juei Huang, Kohei Saeki, Noriko Kanaya, Gregory Chang, George Somlo, Shiuan Chen
Summary: Extensive efforts to characterize the androgen receptor (AR) signaling pathway in triple-negative breast cancer (TNBC) using cell line-based models have not reached a consensus. Patient-derived xenografts (PDXs) were used to identify and molecularly characterize two new AR-positive TNBC PDX models, revealing distinct effects of AR agonist (DHT) and antagonist (enzalutamide) on tumor growth in different PDXs.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2021)
Review
Pharmacology & Pharmacy
Xueqiong Xun, Jun Ai, Fuhui Feng, Pan Hong, Saroj Rai, Ruikang Liu, Baowen Zhang, Yeming Zhou, Huiyong Hu
Summary: This meta-analysis found that the use of Bevacizumab in patients with triple-negative breast cancer and HER-2 negative metastatic breast cancer may increase the incidence of serious adverse events, indicating a need for caution in its usage.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Tatiana J. Carneiro, Rita Araujo, Martin Vojtek, Salome Goncalves-Monteiro, Ana L. M. Batista de Carvalho, Maria Paula M. Marques, Carmen Diniz, Ana M. Gil
Summary: Interest in palladium(II) compounds as potential new anticancer drugs has increased due to their high toxicity and acquired resistance to platinum(II)-derived agents, such as cisplatin. This study examines the in vivo response of TNBC tumors to a Pd(2)Spm complex compared to cisplatin, showing distinct impacts on polar metabolites but not on tumor lipophilic metabolism. The results suggest that the Pd(2)Spm complex triggers more variations in certain metabolites related to cytotoxicity and may have a distinct mechanism of action in TNBC metabolism.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Nanoscience & Nanotechnology
Karen M. Bussard, Christopher M. Gigliotti, Bernadette M. Adair, Jenna M. Snyder, Nicholas T. Gigliotti, Welley S. Loc, Zachary R. Wilczynski, Zi-Kui Liu, Kacey Meisel, Cecilia Zemanek, Andrea M. Mastro, Alison B. Shupp, Christopher McGovern, Gail L. Matters, James H. Adair
Summary: The study demonstrated that targeting anti-CD71-CPSNPs enhanced internalization by triple negative breast cancer cells in vitro, leading to apoptotic responses. CPSNPs may serve as imaging tools and selective drug delivery systems for the treatment of breast cancer metastasized to bone.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
(2021)
Article
Oncology
Amber N. Hurson, Mustapha Abubakar, Alina M. Hamilton, Kathleen Conway, Katherine A. Hoadley, Michael Love, Andrew F. Olshan, Charles M. Perou, Montserrat Garcia-Closas, Melissa A. Troester
Summary: This study identified breast cancer risk factors associated with RNA-based TP53 and ER, providing a new etiologic schema of interest in breast cancer prevention research.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Oncology
Achal Patel, Montserrat Garcia-Closas, Andrew F. Olshan, Charles M. Perou, Melissa A. Troester, Michael Love, Arjun Bhattacharya
Summary: This study identifies race-specific genetic associations with breast cancer risk of recurrence scores and suggests mediation of these associations by PAM50 subtype and expression, with implications for clinical interpretation of these scores.
Review
Immunology
Gratiela Gradisteanu Pircalabioru, Florina Silvia Iliescu, Grigore Mihaescu, Alina Irina Cucu, Octavian Narcis Ionescu, Melania Popescu, Monica Simion, Liliana Burlibasa, Mihaela Tica, Mariana Carmen Chifiriuc, Ciprian Iliescu
Summary: Viral infections are a significant public health problem, and laboratory diagnostic tests play a crucial role in improving patient care and infection prevention. This review discusses the progress and potential of micro- and nanotechnology-based solutions for rapidly detecting human viral respiratory infectious diseases, as well as alternative methods such as microfluidics, biosensors, and IoT-based devices.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Oncology
Carey K. Anders, Mark G. Woodcock, Amanda E. D. Van Swearingen, Dominic T. Moore, Maria J. Sambade, Sonia Laurie, Alexander Robeson, Oleg Kolupaev, Luz A. Cuaboy, Amy L. Garrett, Karen McKinnon, Kristen Cowens, Dante Bortone, Benjamin C. Calhoun, Alec D. Wilkinson, Lisa Carey, Trevor Jolly, Hyman Muss, Katherine Reeder-Hayes, Rebecca Kaltman, Rachel Jankowitz, Vinay Gudena, Oludamilola Olajide, Charles Perou, E. Claire Dees, Benjamin G. Vincent, Jonathan S. Serody
Summary: This study evaluated the efficacy of using a low dose of cyclophosphamide (Cy) to deplete regulatory T cells (T-regs) before initiating pembrolizumab in patients with triple negative breast cancer (TNBC). The results showed that Cy did not significantly decrease T-regs before pembrolizumab and there was a rapid recovery in T-regs after the first cycle of therapy. Baseline samples with increased B cell gene expression were associated with clinical response and immune-related toxicity (IRT).
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Alina M. Hamilton, Amber N. Hurson, Linnea T. Olsson, Andrea Walens, Joseph Nsonwu-Farley, Erin L. Kirk, Yara Abdou, Stephanie M. Downs-Canner, Jonathan S. Serody, Charles M. Perou, Benjamin C. Calhoun, Melissa A. Troester, Katherine A. Hoadley
Summary: The immune microenvironment in breast cancer is closely related to race, age, tumor subtype, and grade. Black and young women have higher immune response, which may be associated with higher recurrence risk.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Oncology
Sonam Bhatia, Melissa Kramer, Suzanne Russo, Payal Naik, Gayatri Arun, Kyle Brophy, Peter Andrews, Cheng Fan, Charles M. Perou, Jonathan Preall, Taehoon Ha, Dennis Plenker, David A. Tuveson, Arvind Rishi, John E. Wilkinson, W. Richard McCombie, Karen Kostroff, David L. Spector
Summary: This study developed a diverse biobank of patient-derived organoids of triple-negative breast cancer (TNBC) and provided comprehensive insights into TNBC biology and progression. The organoids successfully recapitulated patient tumor characteristics and identified potential mechanisms of tumorigenesis at the single-cell level.
Article
Chemistry, Analytical
Florina Silvia Iliescu, Ling Tim Hong, Jin Ming Jaden Toh, Mirela Petruta Suchea, Octavian Narcis Ionescu, Ciprian Iliescu
Summary: Improper foot biomechanics and uneven bodyweight distribution can lead to balance impairments and increased risk of falls. This study presents the development of a user-friendly screening device, the Early Notice Pointer (ENP), based on weighing scale technology. The ENP is designed for at-home measurement of weight-shifting and provides foot and posture triage.
Editorial Material
Oncology
Sarah Asad, Kathryn Kananen, Kurt R. Mueller, W. Fraser Symmans, Yujia Wen, Charles M. Perou, James S. Blachly, James Chen, Benjamin G. Vincent, Daniel G. Stover
JCO CLINICAL CANCER INFORMATICS
(2022)
Article
Oncology
Youli Xia, Xiaping He, Lorna Renshaw, Carlos Martinez-Perez, Charlene Kay, Mark Gray, James Meehan, Joel S. Parker, Charles M. Perou, Lisa A. Carey, J. Michael Dixon, Arran Turnbull
Summary: This study identified molecular mechanisms underlying endocrine therapy resistance (ETR) in hormone receptor-positive breast cancer through in-depth genomic analysis. The results showed that ETR involves diverse changes in somatic genetic and transcriptomic profiles, including mutations, gene expression changes, and activation of signaling pathways. Overcoming resistance will require an individualized approach utilizing genomic and genetic biomarkers and drugs tailored to each patient.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Audrey Y. Jung, Thomas U. Ahearn, Sabine Behrens, Pooja Middha, Manjeet K. Bolla, Qin Wang, Volker Arndt, Kristan J. Aronson, Annelie Augustinsson, Laura E. Beane Freeman, Heiko Becher, Hermann Brenner, Federico Canzian, Lisa A. Carey, Cts Consortium, Kamila Czene, A. Heather Eliassen, Mikael Eriksson, D. Gareth Evans, Jonine D. Figueroa, Lin Fritschi, Marike Gabrielson, Graham G. Giles, Pascal Guenel, Andreas Hadjisavvas, Christopher A. Haiman, Niclas Hakansson, Per Hall, Ute Hamann, Reiner Hoppe, John L. Hopper, Anthony Howell, David J. Hunter, Anika Huesing, Rudolf Kaaks, Veli-Matti Kosma, Stella Koutros, Peter Kraft, James Lacey, Loic Le Marchand, Jolanta Lissowska, Maria A. Loizidou, Arto Mannermaa, Tabea Maurer, Rachel A. Murphy, Andrew F. Olshan, Hakan Olsson, Alpa Patel, Charles M. Perou, Gad Rennert, Rana Shibli, Xiao-Ou Shu, Melissa C. Southey, Jennifer Stone, Rulla M. Tamimi, Lauren R. Teras, Melissa A. Troester, Therese Truong, Celine M. Vachon, Sophia S. Wang, Alicja Wolk, Anna H. Wu, Xiaohong R. Yang, Wei Zheng, Alison M. Dunning, Paul D. P. Pharoah, Douglas F. Easton, Roger L. Milne, Nilanjan Chatterjee, Marjanka K. Schmidt, Montserrat Garcia-Closas, Jenny Chang-Claude
Summary: Reproductive factors are differentially associated with risk of breast cancer subtypes, and triple-negative breast cancer has a distinct reproductive risk factor profile.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Article
Oncology
Aatish Thennavan, Susana Garcia-Recio, Siyao Liu, Xiaping He, Charles M. Perou
Summary: Ductal carcinoma in situ (DCIS) of the breast is a precursor of invasive ductal carcinoma (IDC). This study utilizes mouse models and human samples to identify features associated with DCIS progression. The analysis reveals malignant cells and tumor microenvironmental changes in DCIS and IDC, and suggests the existence of intrinsic subtype unique DCIS features. The findings may contribute to the identification and treatment of progression-prone DCIS in human basal-like breast cancers.
Review
Chemistry, Analytical
Jianguo Feng, Jiri Neuzil, Andreas Manz, Ciprian Iliescu, Pavel Neuzil
Summary: The low success rate, time consumption, and high cost of bringing a drug from concept to market necessitate new approaches to drug discovery. Recent innovations in microfluidic technologies, such as organ-on-a-chip, droplet microfluidics, and high-throughput screening, have shown potential in addressing these challenges through reduced sample volume, faster processing time, and improved process control. This review highlights the recent progress in the development and application of microfluidic technologies in drug screening and drug delivery, outlining the trends and associated challenges.
TRAC-TRENDS IN ANALYTICAL CHEMISTRY
(2023)
Article
Oncology
David C. Boyd, Emily K. Zboril, Amy L. Olex, Tess J. Leftwich, Nicole S. Hairr, Holly A. Byers, Aaron D. Valentine, Julia E. Altman, Mohammad A. Alzubi, Jacqueline M. Grible, Scott A. Turner, Andrea Ferreira-Gonzalez, Mikhail G. Dozmorov, J. Chuck Harrell
Summary: Basal-like breast cancers, which are the majority of triple-negative breast cancers, have high levels of PI3K pathway activity and are difficult to treat. PI3K inhibitors as single agents have limited efficacy in TNBC patients. This study aimed to identify drug combinations that can effectively inhibit tumor growth when used in conjunction with PI3K inhibitors.
Article
Oncology
Frederick M. Howard, James Dolezal, Sara Kochanny, Galina Khramtsova, Jasmine Vickery, Andrew Srisuwananukorn, Anna Woodard, Nan Chen, Rita Nanda, Charles M. Perou, Olufunmilayo I. Olopade, Dezheng Huo, Alexander T. Pearson
Summary: Gene expression-based recurrence assays are recommended for guiding chemotherapy in hormone receptor-positive, HER2-negative breast cancer, but their high cost and limited availability pose challenges. This study presents a deep learning model that utilizes digital histology and clinical risk factors to predict recurrence assay results and the risk of recurrence, surpassing the performance of established clinical nomograms. The model can identify patients with excellent prognoses who may not require further genomic testing.
Review
Biochemistry & Molecular Biology
Violeta Dediu, Jana Ghitman, Gratiela Gradisteanu Pircalabioru, Kiat Hwa Chan, Florina Silvia Iliescu, Ciprian Iliescu
Summary: The rapid development of antimicrobial resistance due to broad antibiotic utilization in healthcare and food industries is a critical global public health issue. Nanotechnology offers new materials with unique properties and adaptability to address drug-resistant bacterial infections in safe and targeted ways. Photothermal antibacterial nanomaterials, such as plasmonic metals, semiconductors, and organic polymers, show promise in developing controllable hyperthermia as antibacterial platforms. This review discusses the current state of the art in photothermal antibacterial nanomaterials, strategies for optimizing antimicrobial efficiency, antibacterial mechanisms, and potential applications in biofilm removal and infected wound therapy. The challenges, limitations, and future perspectives of photothermal antimicrobial therapy are also explored.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)